Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
International Journal of Oncology|December 22, 2007
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of schedulingCristina Oliveras-Ferraros, Alejandro Vazquez-Martin, Ramon Colomer, et al.
International Journal of Molecular Medicine|June 6, 2007
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)Laura Ferrer-Soler, Alejandro Vazquez-Martin, Joan Brunet, et al.
Cell Cycle (Georgetown, Tex.)|December 1, 2011
Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotypeSílvia Cufí, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, et al.
Aging|June 21, 2012
Mitochondrial fusion by pharmacological manipulation impedes somatic cell reprogramming to pluripotency: new insight into the role of mitophagy in cell stemnessAlejandro Vazquez-Martin, Sílvia Cufi, Bruna Corominas-Faja, et al.
Molecular Carcinogenesis|July 11, 2007
BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancerJoan Brunet, Alejandro Vazquez-Martin, Ramon Colomer, et al.
Oncology Reports|November 21, 2008
Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profilingEugeni López-Bonet, Miguel Alonso-Ruano, Graciela Barraza, et al.
Cell Cycle (Georgetown, Tex.)|November 20, 2010
Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosisSilvia Cufí, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, et al.
Cell Cycle (Georgetown, Tex.)|October 5, 2010
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) statusAlejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Silvia Cufí, et al.
Journal of Cellular Physiology|July 27, 2010
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growthAlejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Silvia Cufí, et al.
Nucleus (Austin, Tex.)|January 10, 2017
Nucleolar aggresomes mediate release of pericentric heterochromatin and nuclear destruction of genotoxically treated cancer cellsKristine Salmina, Anda Huna, Inna Inashkina, et al.
Pageof 8